Inhibition of acute lymphoblastic and myeloid leukemias by a novel kinase inhibitor

Blood

Volumn 102, Issue 12, 2003, Pages 4153-4158

  Grunberger, Thomas ^b   Demin, Peter ^b   Rounova, Olga ^b   Sharfe, Nigel ^b   Cimpean, Lorand ^b   Dadi, Harjit ^b   Freywald, Andrew ^b   Estrov, Zeev ^b   Roifman, Chaim M ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 (BENZYLAMINOCARBONYL) 3 (3,4 DIHYDROXYSTYRYL)ACRYLONITRILE; CR 4; IMATINIB; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; MOUSE; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL;

EID: 0344394472     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-03-0860     Document Type: Article

References (48)

1. Chopra R, Pu QQ, Elefanty AG. Biology of BCR-ABL. Blood Rev. 1999;13:211-229.
2. Arlinghaus RB. The involvement of Bcr in leukemias with the Philadelphia chromosome. Crit Rev Oncog. 1998;9:1-18.
3. Sattler M, Griffin JD. Mechanisms of transformation by the BCR/ABL oncogene. Int J Hematol. 2001;73:278-291.
4. Parada Y, Banerji L, Glassford J, et al. BCR-ABL and interleukin 3 promote hematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression. J Biol Chem. 2001;276:23572-23580.
5. Raitano AB, Whang YE, Sawyers CL. Signal transduction by wild-type and leukemogenic Abl proteins. Biochim Biophys Acta. 1997;1333:F201-F216.
6. Keeshan K, Mills KI, Cotter TG, McKenna SL. Elevated Bcr-Abl expression levels are sufficient for a hematopoietic cell line to acquire a drug-resistant phenotype. Leukemia. 2001;15:1823-1833.
7. Levitzki A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol Ther. 1999;82:231-239.
8. Traxler P, Bold G, Buchdunger E, et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev. 2001;21:499-512.
9. Meydan N, Grunberger T, Dadi H, et al. Inhibition of acute lymphoblastic leukemia by a Jak-2 inhibitor. Nature. 1996;379:645-648.
10. Ito T, May WS. Drug development train gathering steam. Nat Med. 1996;2:403-404.
11. Griffin J. The biology of signal transduction inhibition: basic science to novel therapies. Semin Oncol. 2001;28:3-8.
12. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100-104.
13. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997;90:4947-4952.
14. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997;90:3691-3698.
15. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
16. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139-145.
17. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925-932.
18. Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol. 2002;20:325-334.
19. Druker, BJ. Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia. Semin Hematol. 2001;38:9-14.
20. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
21. le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. 2000;95:1758-1766.
22. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood. 2000;95:3498-3505.
23. Weisberg E, Griffin JD. Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients. Drug Resist Updat. 2001;4:22-28.
24. Hochhaus A, Kreil S, Corbin A, et al. Roots of clinical resistance to STI-571 cancer therapy. Science. 2001;293:2163.
25. Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000;96:1070-1079.
26. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876-880.
27. Estrov Z, Talpaz M, Zipf TF, et al. Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181). J Cell Physiol. 1996;166:618-630.
28. Estrov Z, Talpaz M, Ku S, et al. Molecular and biologic characterization of a newly established Philadelphia-positive acute lymphoblastic leukemia cell line (Z-33) with an autocrine response to GM-CSF. Leukemia. 1996;10:1534-1543.
29. Estrov Z, Grunberger T, Dube ID, Wang YP, Freedman MH. Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission. N Engl J Med. 1986;315:538-542.
30. Fauser AA, Messner HA. Granuloerythropoietic colonies in human bone marrow, peripheral blood, and core blood. Blood. 1978;52:1243-1248.
31. Messner HA, Fauser AA. Culture studies of human pluripotent hematopoietic progenitors. Blut. 1980;41:327-333.
32. Sharfe N, Dadi HK, Roifman CM. JAK3 protein tyrosine kinase mediates interleukin-7-induced activation of phosphatidylinositol-3′ kinase. Blood. 1995;86:2077-2085.
33. Al-Shami A, Naccache PH. Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils: involvement of Jak2 in the stimulation of phosphatidylinositol 3-kinase. J Biol Chem. 1999;274:5333-5338.
34. Aringer M, Cheng A, Nelson JW, et al. Janus kinases and their role in growth and disease. Life Sci. 1999;64:2173-2186.
35. Ihle JN, Witthuhn BA, Quelle FW, Yamamoto K, Silvennoinen O. Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol. 1995;13:369-398.
36. Ihle JN, Thierfelder W, Teglund S, et al. Signaling by the cytokine receptor superfamily. Ann N Y Acad Sci. 1998;865:1-9.
37. Spiekermann K, Biethahn S, Wilde S, Hiddemann W, Alves F. Constitutive activation of STAT transcription factors in acute myelogenous leukemia. Eur J Haematol. 2001;67:63-71.
38. Holyoake DT. Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. Br J Haematol. 2001;113:11-23.
39. Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 1999;96:12804-12809.
40. Nakajima A, Tauchi T, Ohyashiki K. ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis. Leukemia. 2001;15:989-990.
41. Okuda K, Weisberg E, Gilliland DG, Griffin JD. ARG tyrosine kinase activity is inhibited by STI571. Blood. 2001;97:2440-2448.
42. Sun X, Layton JE, Elefanty A, Lieschke GJ. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL - expressing cells, demonstrating synergy between AG490 and STI571. Blood. 2001;97:2008-2015.
43. Bohlander SK. Fusion genes in leukemia: an emerging network. Cytogenet Cell Genet. 2000;91:52-56.
44. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278:1309-1312.
45. + leukemic cells and induces apoptosis. Blood Cells Mol Dis. 1997;23:380-394.
46. Nielsen M, Kaltoff K, Nordahl M, et al. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci U S A. 1997;94:6764-6769.
47. Constantin G, Brocke S, Izikson A, Laudanna C, Butcher EC. Tyrphostin AG490, a tyrosine kinase inhibitor, blocks actively induced experimental autoimmune encephalomyelitis. Eur J Immunol. 1998;28:3523-3529.
48. Dadi H, Ke S, Roifman CM. Activation of phosphatidylinositol-3 kinase by ligation of the interleukin-7 receptor is dependent on protein tyrosine kinase activity. Blood. 1994;84:1579-1586.